Stand Up To Cancer announced a second SU2C Catalyst collaboration with Genentech, a member of the Roche Group, aimed at accelerating the development of new cancer treatments and combination therapies through clinical trials using Genentech medicines, including both commercial and pre-commercial treatments.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
